HBC plans a pilot study to assess the peptides as a treatment for maintaining disease remission in people with mild to moderate ulcerative colitis. This is expected to commence in 2021.

SAN DIEGO -- Treatment with hydroxyurea led to more hematologic dose-limiting toxicities (DLTs) compared with placebo in patients with hemoglobin SC, a milder form of sickle cell disease (SCD), a ...